Form 13-F position report

RAPID MICRO BIOSYSTEMS INC

Reported by KENNEDY LEWIS MANAGEMENT LP

RPID CUSIP 75340L104 Manager CIK 0001797633

Reported 4,939,931 shares, unchanged from the prior quarter.

Reported value -23.7%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 16.97% This manager · Q2 2023
Shares 4,939,931 Quarter-end amount reported
Reported value $4,939,931 Fair value at quarter end
Consecutive quarters held 7 Through Q2 2023

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 3822000
2022-03-31 12666000
2022-06-30 21242000
2022-09-30 15956000
2022-12-31 5582122
2023-03-31 6471310
2023-06-30 4939931
2023-09-30 5335125
2023-12-31 3655549
2024-03-31 4791733
2024-06-30 3260354
2024-09-30 4396539

Quarterly position history

How this manager's reported quarter-end position changed over time.

12 quarters
Quarterly reported position history for RAPID MICRO BIOSYSTEMS INC held by KENNEDY LEWIS MANAGEMENT LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2024 Unchanged 4,939,931 0 (0.0%) 20.1% $4,396,539 2024-10-18
Q2 2024 Unchanged 4,939,931 0 (0.0%) 14.06% $3,260,354 2024-08-13
Q1 2024 Unchanged 4,939,931 0 (0.0%) 20.73% $4,791,733 2024-04-30
Q4 2023 Unchanged 4,939,931 0 (0.0%) 20.25% $3,655,549 2024-02-14
Q3 2023 Unchanged 4,939,931 0 (0.0%) 25.51% $5,335,125 2023-11-13
Q2 2023 Unchanged 4,939,931 0 (0.0%) 16.97% $4,939,931 2023-08-11
Q1 2023 Unchanged 4,939,931 0 (0.0%) 17.03% $6,471,310 2023-05-10
Q4 2022 Unchanged 4,939,931 0 (0.0%) 8.41% $5,582,122 2023-02-10
Q3 2022 Unchanged 4,939,931 0 (0.0%) 18.21% $15,956,000 2022-11-14
Q2 2022 Added 4,939,931 +3,074,519 (164.8%) 23.35% $21,242,000 2022-08-15
Q1 2022 Added 1,865,412 +1,506,262 (419.4%) 7.87% $12,666,000 2022-05-16
Q4 2021 New 359,150 +359,150 (0.0%) 2.55% $3,822,000 2022-02-11

Who else reported the position

35 managers reported RAPID MICRO BIOSYSTEMS INC for Q2 2023.

Managers reporting RAPID MICRO BIOSYSTEMS INC in Q2 2023.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bain Capital Life Sciences Investors LLC Unchanged 8,434,560 0 0.87% $8,434,560 8 qtrs
KENNEDY LEWIS MANAGEMENT LP This report Unchanged 4,939,931 0 16.97% $4,939,931 7 qtrs
JPMorgan Chase & Co Reduced 1,435,707 -19,454 < 0.01% $1,435,707 8 qtrs
GLENVIEW CAPITAL MANAGEMENT LLC Added 1,318,288 +500,000 0.03% $1,318,288 6 qtrs
ABG-WTT Global Life Science Capital Partners GP Ltd Unchanged 1,038,296 0 18.84% $1,038,296 6 qtrs
BlackRock Inc Added 1,034,861 +7,801 < 0.01% $1,034,861 8 qtrs
The Goldman Sachs Group Inc Reduced 941,357 -2,983 < 0.01% $941,357 8 qtrs
VANGUARD GROUP INC Unchanged 729,600 0 < 0.01% $729,600 8 qtrs
ADAGE CAPITAL PARTNERS GP L L C Unchanged 700,000 0 < 0.01% $700,000 8 qtrs
KHAZANAH NASIONAL BERHAD Unchanged 648,905 0 0.14% $648,905 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2023
Filed
August 11, 2023
Filing type
13F-HR
Position type
CLASS A COM

Voting authority reported

Sole
4,939,931
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.